{"id":"evolocumab-combined-with-statins","safety":{"commonSideEffects":[{"rate":"2-3","effect":"Injection site reactions"},{"rate":"5-10","effect":"Nasopharyngitis"},{"rate":"5-10","effect":"Upper respiratory tract infection"},{"rate":"2-5","effect":"Muscle pain or myalgia"},{"rate":"2-5","effect":"Headache"}]},"_chembl":null,"_fixedAt":"2026-03-30T14:05:18.769460","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Evolocumab binds to proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that normally degrades LDL receptors on hepatocytes. By blocking PCSK9, evolocumab preserves LDL receptors on the liver surface, enabling more efficient removal of LDL cholesterol from circulation. When combined with statins, which reduce cholesterol synthesis, the dual mechanism produces additive LDL-lowering effects beyond either agent alone.","oneSentence":"Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream, and is combined with statins to achieve greater LDL-lowering efficacy.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:36:40.962Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypercholesterolemia (primary and secondary prevention of cardiovascular events)"},{"name":"Familial hypercholesterolemia"}]},"_fixedFields":["pubmed(143)"],"trialDetails":[{"nctId":"NCT04862260","phase":"EARLY_PHASE1","title":"Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"CHU de Quebec-Universite Laval","startDate":"2021-10-04","conditions":"Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Pancreas Cancer","enrollment":3},{"nctId":"NCT06696820","phase":"PHASE2, PHASE3","title":"Efficacy and Safety of Early Combined Therapy With PCSK9 Inhibitors and Statins in Acute Ischemic Stroke","status":"RECRUITING","sponsor":"Xiang Luo","startDate":"2024-11-29","conditions":"Acute Ischemic Stroke","enrollment":429},{"nctId":"NCT06738758","phase":"","title":"Multicenter Real-World Cohort Study Evaluating the Impact of Early Intensive Lipid-Lowering Therapy on the Prognosis of Acute Coronary Syndrome Patients(ELITE-ACS)","status":"RECRUITING","sponsor":"Yun Dai Chen","startDate":"2024-12-16","conditions":"Acute Coronary Syndromes","enrollment":6000},{"nctId":"NCT05537948","phase":"PHASE4","title":"Efficacy and Safety of Pitavastatin and PCSK9 Inhibitors in Liver Transplant Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Medical Research Center for Therapy and Preventive Medicine","startDate":"2021-10-01","conditions":"Dyslipidemias, Hyperlipidemias, Liver Transplant Disorder","enrollment":59},{"nctId":"NCT05613426","phase":"PHASE4","title":"Effect of Very Early and Rapid Lowering Cholesterol With Evolocumab on Left Ventricular Remodeling in Patients With Anterior STEMI Undergoing Primary PCI","status":"RECRUITING","sponsor":"Henan Institute of Cardiovascular Epidemiology","startDate":"2023-04-03","conditions":"ST Elevation Myocardial Infarction (STEMI)","enrollment":330},{"nctId":"NCT01764633","phase":"PHASE3","title":"Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-02-08","conditions":"Dyslipidemia","enrollment":27564},{"nctId":"NCT06381947","phase":"PHASE4","title":"Efficacy and Safety of Bempedoic Acid in Association With Anti-PCSK9 and Ezetimibe in Statin-intolerant Patients","status":"NOT_YET_RECRUITING","sponsor":"University of Salerno","startDate":"2024-05-01","conditions":"Dyslipidemias, Statin Adverse Reaction, Cardiovascular Diseases","enrollment":130},{"nctId":"NCT05624658","phase":"NA","title":"Effect of Combined Lipid-lowering Therapy on Atherosclerotic Plaque Vulnerability in Patients With ACS","status":"UNKNOWN","sponsor":"Samara Regional Cardiology Dispensary","startDate":"2022-09-02","conditions":"Dyslipidemias","enrollment":200},{"nctId":"NCT04608474","phase":"PHASE4","title":"Lipid Management in Renal Transplant Recipients Using Evolocumab.","status":"UNKNOWN","sponsor":"Brigham and Women's Hospital","startDate":"2021-02-17","conditions":"Hyperlipidemias","enrollment":120},{"nctId":"NCT05802108","phase":"PHASE4","title":"Effect of PCSK9 Inhibitor on Retinal Microvessels in Patients With Coronary Heart Disease After Intensive Lipid-lowering Therapy","status":"UNKNOWN","sponsor":"Zibo Central Hospital","startDate":"2022-07-01","conditions":"Adverse Effect of Cardiovascular Medications (Diagnosis)","enrollment":60},{"nctId":"NCT03932721","phase":"PHASE4","title":"EXpanded Combination of Evolocumab Plus Empagliflozin on Diabetes: EXCEED-BHS3 Trial","status":"COMPLETED","sponsor":"University of Campinas, Brazil","startDate":"2018-10-01","conditions":"Dyslipidemia Associated With Type II Diabetes Mellitus, Diabetes Mellitus, Type 2, Hypertension Arterial","enrollment":110},{"nctId":"NCT05697185","phase":"PHASE4","title":"Safety and Efficacy of Evolocumab in Ischemic Stroke","status":"UNKNOWN","sponsor":"Second Affiliated Hospital of Guangxi Medical University","startDate":"2023-02-01","conditions":"Ischemic Stroke, Acute","enrollment":200},{"nctId":"NCT01380730","phase":"PHASE2","title":"LAPLACE-TIMI 57: Low-density Lipoprotein Cholesterol (LDL-C) Assessment With PCSK9 monoclonaL Antibody Inhibition Combined With Statin thErapy","status":"COMPLETED","sponsor":"Amgen","startDate":"2011-07-01","conditions":"Hyperlipidemia","enrollment":631},{"nctId":"NCT01763866","phase":"PHASE3","title":"LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-01-15","conditions":"Hyperlipidemia","enrollment":2067},{"nctId":"NCT04087915","phase":"","title":"Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With High Risk Coronary Artery Disease (FORWARD)","status":"UNKNOWN","sponsor":"Beijing Anzhen Hospital","startDate":"2019-09-11","conditions":"Dyslipidemia, High Risk Coronary Artery Disease","enrollment":1000},{"nctId":"NCT02662569","phase":"PHASE3","title":"Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia","status":"COMPLETED","sponsor":"Amgen","startDate":"2016-04-14","conditions":"Diabetes, Hyperlipidemia, Mixed Dyslipidemia","enrollment":986},{"nctId":"NCT01652703","phase":"PHASE2","title":"A Study to Evaluate Tolerability and Efficacy of Evolocumab (AMG 145) in Japanese Subjects","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-07-10","conditions":"Hypercholesterolemia and High Risk for Cardiovascular Events","enrollment":310},{"nctId":"NCT01953328","phase":"PHASE3","title":"Study of Low-Density Lipoprotein Cholesterol (LDL-C) Reduction Using Evolocumab (AMG 145) in Japanese Patients With Advanced Cardiovascular Risk","status":"COMPLETED","sponsor":"Amgen","startDate":"2013-10","conditions":"Hyperlipidemia or Mixed Dyslipidemia at High Risk for Cardiovascular Events","enrollment":409}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":143,"recentPublications":[{"date":"2026 Mar 11","pmid":"41807944","title":"Effects of evolocumab combined with statin therapy on blood lipids, inflammatory factors, and endothelial function in patients with coronary heart disease.","journal":"BMC cardiovascular disorders"},{"date":"2026 Mar 3","pmid":"41775756","title":"PCSK9 inhibitors patterns of use in France from nationwide repeated cross-sectional and cohort studies.","journal":"Scientific reports"},{"date":"2026","pmid":"41601579","title":"Impact of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors on intracranial atherosclerotic plaque characteristics and low density lipoprotein-cholesterol (LDL-C) reduction: a real-world observational study.","journal":"PeerJ"},{"date":"2025 Dec","pmid":"41111438","title":"Cost-effectiveness of non-statin lipid-lowering therapies as an add-on to statins for achieving low-density lipoprotein cholesterol therapeutic targets in very high-risk patients in the Spanish setting.","journal":"Journal of medical economics"},{"date":"2025 Sep 25","pmid":"41095514","title":"Medical and Financial Consequences of Using PCSK9 Inhibitors for Managing Hypercholesterolemia in Saudi Arabia: A Historical Cohort Study.","journal":"Healthcare (Basel, Switzerland)"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["drug1"],"phase":"marketed","status":"active","brandName":"Evolocumab combined with statins","genericName":"Evolocumab combined with statins","companyName":"Zibo Central Hospital","companyId":"zibo-central-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Evolocumab is a monoclonal antibody that inhibits PCSK9, allowing increased clearance of LDL cholesterol from the bloodstream, and is combined with statins to achieve greater LDL-lowering efficacy. Used for Hypercholesterolemia (primary and secondary prevention of cardiovascular events), Familial hypercholesterolemia.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}